A mid-stage trial for Amgen’s obesity candidate MariTide has shown substantial weight loss results, but also a high rate of side effects and discontinuations among patients. The Phase 2 study found that patients taking the injectable drug lost up to 16.2% of their weight over one year, with those who completed treatment losing as much as 19.9%. The results are consistent with Amgen’s decision to use a slower dosing schedule in further testing. The trial also showed benefits for patients with obesity and type 2 diabetes, including weight loss of up to 12.3% among all participants and up to 17% among those who stayed on treatment.
Source: https://www.statnews.com/2025/06/23/amgen-maritide-obesity-drug-trial-discontinuations-side-effects-dosing-changes